Evidence map›Paper›PMID 32626922›Full record

ReviewInternational journal of molecular medicine2020

A dissection of SARS‑CoV2 with clinical implications (Review).

Felician Stancioiu, Georgios Z Papadakis, Stelios Kteniadakis, Boris Nikovaevich Izotov, Michael D Coleman, Demetrios A Spandidos, Aristidis Tsatsakis

Abstract readReview
In one paragraph

Review in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. A Review on Role of Inflammation in Coronavirus Disease.Endocrine, metabolic & immune disorders drug targets · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Role of phytoconstituents in the management of COVID-19.Chemico-biological interactions · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Felician StancioiuBio‑Forum Foundation, 030121 Bucharest, Romania.
Georgios Z PapadakisDepartment of Radiology, Medical School, University of Crete, 71003 Heraklion, Greece.
Stelios KteniadakisEmergency Department, Venizeleion General Hospital, 71409 Heraklion, Greece.
Boris Nikovaevich IzotovDepartment of Analytical and Forensic Medical Toxicology, Sechenov University, 119991 Moscow, Russia.
Michael D ColemanSchool of Life and Health Sciences, Aston University, B4 7ET Birmingham, UK.
Demetrios A SpandidosLaboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Greece.
Aristidis TsatsakisDepartment of Analytical and Forensic Medical Toxicology, Sechenov University, 119991 Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We are being confronted with the most consequential pandemic since the Spanish flu of 1918‑1920 to the extent that never before have 4 billion people quarantined simultaneously; to address this global challenge we bring to the forefront the options for medical treatment and summarize SARS‑CoV2 structure and functions, immune responses and known treatments. Based on literature and our own experience we propose new interventions, including the use of amiodarone, simvastatin, pioglitazone and curcumin. In mild infections (sore throat, cough) we advocate prompt local treatment for the naso‑pharynx (inhalations; aerosols; nebulizers); for moderate to severe infections we propose a tried‑and‑true treatment: the combination of arginine and ascorbate, administered orally or intravenously. The material is organized in three sections: i) Clinical aspects of COVID‑19; acute respiratory distress syndrome (ARDS); known treatments; ii) Structure and functions of SARS‑CoV2 and proposed antiviral drugs; iii) The combination of arginine‑ascorbate.

Indexed as

AmiodaroneAnimalsCOVID-19CurcuminHumansPioglitazoneRespiratory Distress SyndromeSARS-CoV-2SimvastatinAmiodaroneCurcuminPioglitazoneSimvastatin

Identifiers

PMID32626922
PMCPMC7307812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.